Tuesday, November 7, 2017
- 9:00AM-11:00AM
-
Abstract Number: 2265
Survey on Gout-Related Knowledge and Perception in Inpatient Setting on Hospitalized Patients with Gout
Patient Outcomes, Preferences, and Attitudes Poster III- 9:00AM-11:00AM
-
Abstract Number: 2490
Sustained Clinical Response in Refractory Rheumatoid Arthritis Patients with a Low-Dose Rituximab Retreatment Regimen. a Single Center Experience
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster III: Efficacy and Safety of Originator Biologics and Biosimilars- 9:00AM-11:00AM
-
Abstract Number: 1929
Sustained Efficacy of Intra-Articular SB-061, a Novel Matrix Regulator Inspired By Aggrecan, in a Rat Model of Osteoarthritis
Biology and Pathology of Bone and Joint Poster II- 9:00AM-11:00AM
-
Abstract Number: 2471
Sustained Response in a Phase 3 Study of Sarilumab Plus Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients with Active, Moderate-to-Severe Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster III: Efficacy and Safety of Originator Biologics and Biosimilars- 9:00AM-11:00AM
-
Abstract Number: 2439
Switching from RA Originator to Biosimilar in Routine Clinical Care: Early Data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy Poster III: Efficacy and Safety of Originator Biologics and Biosimilars- 9:00AM-11:00AM
-
Abstract Number: 2315
Symptoms of Depression and Anxiety in Children with JIA: Relation to Other Domains of Health Related Quality of Life
Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster III: Juvenile Arthritis- 9:00AM-11:00AM
-
Abstract Number: 2081
Synovial Fluid Leukocyte Count and Its Association with Crystal Deposition in Asymptomatic Hyperuricemia
Metabolic and Crystal Arthropathies Poster II- 9:00AM-11:00AM
-
Abstract Number: 2605
Systematic Review, and Meta-Analysis of Steroid-Sparing Effect, of Biologic Agents in Randomized Placebo-Controlled Phase 3 Trials for Systemic Lupus Erythematosus
Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster III: Therapeutics and Clinical Trial Design- 9:00AM-11:00AM
-
Abstract Number: 2197
Systemic Inflammation and Physical Function in Knee Osteoarthritis
Osteoarthritis – Clinical Aspects Poster II: Observational and Epidemiological Studies- 9:00AM-11:00AM
-
Abstract Number: 2629
Systemic Lupus Erythematosus Patients Not Complaining Raynaud’s Phenomenon Display Lower Skin Blood Perfusion Than Healthy Subjects
Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster III: Therapeutics and Clinical Trial Design- 9:00AM-11:00AM
-
Abstract Number: 2697
Systemic Sclerosis Quality of Life Questionnaire (SScQoL) Captures the Complex Problems Experienced By Patients with Scleroderma
ARHP Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster- 9:00AM-11:00AM
-
Abstract Number: 2098
Systemic Treatment for ACUTE Anterior Uveitis ( SYNTHETIC AND BIOLOGIC DISEASE-MODIFYINGANTIRHEUMATIC DRUGS) : A Systematic Literature Review
Miscellaneous Rheumatic and Inflammatory Diseases Poster II- 9:00AM-11:00AM
-
Abstract Number: 2706
T Follicular-Helper CELLS (TFH) Enrichment and T Follicular-Regulatory CELLS (TFR) Exclusion from Ectopic Germinal Centers in Salivary Glands of Sjogren’s Syndrome Patients
T Cell Biology and Targets in Autoimmune Disease Poster II- 9:00AM-11:00AM
-
Abstract Number: 2608
Tacrolimus in Non-Asian Systemic Lupus Erythematosus Patients: A Real-Life Experience from Three European Centers